Auteur E. J. LAFORGUE

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

ESCAPE Study: Cannabidiol use in patients treated for substance use disorders, prevalence of use, and characteristics of users

M. DUVAL ; M. ISTVAN ; M. ROUSSELET ; E. J. LAFORGUE ; M. GRALL-BRONNEC ; C. MAURIAT ; C. VICTORRI-VIGNEAU | 2025
Dans European Addiction Research (Vol.31, n°1, April 2025) Article : Périodique

INTRODUCTION: Cannabidiol (CBD) is one of the two primary phytocannabinoids found in cannabis. Its diverse pharmacological properties suggest potential benefits for a wide range of medical conditions. The primary objective of this study was to e[...]

Plus d'info

Ajouter à la sélection

Lien externe

French national addictovigilance follow-up of zolpidem between 2014 and 2020: Evolution of drug abuse, misuse and dependence before and after the regulatory change

A. AQUIZERATE ; E. J. LAFORGUE ; M. ISTVAN ; M. ROUSSELET ; M. GÉRARDIN ; E. JOUANJUS ; F. LIBERT ; French Addictovigilance Network ; M. GUERLAIS ; C. VICTORRI-VIGNEAU | 2023
Dans European Journal of Public Health (Vol.33, n°2, April 2023) Article : Périodique

BACKGROUND: Since the appearance of zolpidem on the market, the occurrence of serious cases of abuse, misuse and dependence have come to the attention of authorities. In view of the increase in the number and severity of cases among zolpidem use[...]

Plus d'info

Ajouter à la sélection

Lien externe

How do people who use drugs receiving Opioid Medication Therapy perceive their treatment? A multicentre study

M. GUILLOU-LANDREAT ; A. DANY ; G. CHALLET-BOUJU ; E. J. LAFORGUE ; J. CHOLET ; J. LEBOUCHER ; J. B. HARDOUIN ; C. VICTORRI-VIGNEAU ; M. GRALL-BRONNEC | 2022
Dans Harm Reduction Journal (Vol.19, 2022) Article : Périodique

BACKGROUND: The resurgence of heroin use and the misuse of pharmaceutical opioids are some of the reasons for a worldwide increase in opioid dependence. Opioid Medication Therapies (OMT) have amply demonstrated their efficacy. From a medical poi[...]

Plus d'info

Ajouter à la sélection

Lien externe

"Naloxone? Not for me!" First cross-assessment by patients and healthcare professionals of the risk of opioid overdose

A. AQUIZERATE ; M. ROUSSELET ; A. COCHARD ; M. GUERLAIS ; M. GÉRARDIN ; E. LEFEBVRE ; M. DUVAL ; E. J. LAFORGUE ; C. VICTORRI-VIGNEAU | 2024
Dans Harm Reduction Journal (Vol.21, 2024) Article : Périodique

BACKGROUND: Opioid-related mortality is a rising public health concern in France, where opioids were in 2021 implicated in 75% of overdose deaths. Opioid substitution treatment (OST) was implicated in almost half of deaths related to substance a[...]

Plus d'info

Ajouter à la sélection

Lien externe

Nitrous oxide in France: Evolution of complications reported to the French monitoring system in the context of information from health authorities and regulatory measures

M. GUERLAIS ; A. AQUIZERATE ; A. DAVELUY ; A. LIONNET ; M. GÉRARDIN ; M. DUVAL ; M. ISTVAN ; E. J. LAFORGUE ; C. VICTORRI-VIGNEAU ; French Addictovigilance Network | 2025
Dans International Journal of Drug Policy (Vol.144 Part 2, October 2025) Article : Périodique

Background: In France, the increasing use of nonmedical nitrous oxide (N2O) among young consumers has become a concern. Faced with this increase in consumption, authorities have set up information campaigns and have taken regulatory measures to [...]

Plus d'info

Ajouter à la sélection

Lien externe

Nitrous oxide: a unique official French addictovigilance national survey

M. GUERLAIS ; A. AQUIZERATE ; A. LIONNET ; A. DAVELUY ; M. DUVAL ; M. GÉRARDIN ; M. ISTVAN ; E. J. LAFORGUE ; C. VICTORRI-VIGNEAU | 2023
Dans Frontiers in Public Health (Vol.11, 2023) Article : Périodique

INTRODUCTION: Nitrous oxide has become over the last few years a public health problem in many countries. France has a dedicated health monitoring system dedicated to the surveillance of the abuse, dependence and consequences associated with the[...]

Plus d'info

Ajouter à la sélection

Lien externe

Physicians, pharmacists and take-home naloxone: What practices? The SINFONI study

M. DUVAL ; A. AQUIZERATE ; E. JAULIN ; M. ROUSSELET ; E. KUHN ; A. GUILLEMINOT ; I. NICOLLEAU ; S. PELE ; T. HERAULT ; P. ARTARIT ; E. SOULIDOU-JACQUES ; E. J. LAFORGUE ; C. VICTORRI-VIGNEAU | 2024
Dans Therapies (Vol.79, n°6, Novembre-Décembre 2024) Article : Périodique

Objective: For several years, both the French Addictovigilance Network and French health authorities have consistently emphasized the need to provide opioid users with take-home naloxone (THN), the specific antidote for opioid overdoses. In Marc[...]

Plus d'info

Ajouter à la sélection

Lien externe

Prevalence of coaddictions and rate of successful treatment among a French sample of opioid-dependent patients with long-term opioid substitution therapy: The OPAL Study

M. GRALL-BRONNEC ; E. J. LAFORGUE ; G. CHALLET-BOUJU ; J. CHOLET ; J. B. HARDOUIN ; J. LEBOUCHER ; M. GUILLOU-LANDREAT ; C. VICTORRI-VIGNEAU ; OPAL Group | 2019
Dans Frontiers in Psychiatry (Vol.10, 2019) Article : Périodique

Background: Opioid use disorder (OUD) is a worldwide major health concern due to increased early mortality and morbidity. Opioid substitution therapy (OST) is approved in the context of a global OUD treatment (OUDT), in conjunction with psychoso[...]

Plus d'info

Ajouter à la sélection

Lien externe